Reviva Pharmaceuticals Holdings, Inc. (RVPH) stock
RVPHOTCPharmaceutical PreparationsFiscal year ends December 31
$0.45−0.02 (-4.36%)
Close on Oct 19, 2026Market cap $5.94MP/E –Yield –
Reviva Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Reviva Pharmaceuticals's cash was $17.46M at Sep 30, 2026. For fiscal 2025 it was $14.44M, up 7.1% from the year before. The highest annual figure on record is $29.69M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.44M | +7.1% |
| FY2024 | Dec 31, 2024 | $13.48M | -42.3% |
| FY2023 | Dec 31, 2023 | $23.37M | +26.2% |
| FY2022 | Dec 31, 2022 | $18.52M | -37.6% |
| FY2021 | Dec 31, 2021 | $29.69M | +238.9% |
| FY2020 | Dec 31, 2020 | $8.76M | +4538999.5% |
| FY2019 | Dec 31, 2019 | $193 | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $17.46M | +32.4% |
| Q2 FY2026 | Jun 30, 2026 | $19.89M | +91.9% |
| Q1 FY2026 | Mar 31, 2026 | $22.19M | +319.5% |
| Q4 FY2025 | Dec 31, 2025 | $14.44M | +7.1% |
| Q3 FY2025 | Sep 30, 2025 | $13.18M | +137.2% |
| Q2 FY2025 | Jun 30, 2025 | $10.36M | +67.7% |
| Q1 FY2025 | Mar 31, 2025 | $5.29M | -55.8% |
| Q4 FY2024 | Dec 31, 2024 | $13.48M | -42.3% |
| Q3 FY2024 | Sep 30, 2024 | $5.56M | +11.8% |
| Q2 FY2024 | Jun 30, 2024 | $6.18M | -44.6% |
| Q1 FY2024 | Mar 31, 2024 | $11.97M | +6.4% |
| Q4 FY2023 | Dec 31, 2023 | $23.37M | +26.2% |
| Q3 FY2023 | Sep 30, 2023 | $4.97M | -78.6% |
| Q2 FY2023 | Jun 30, 2023 | $11.15M | -42.6% |
| Q1 FY2023 | Mar 31, 2023 | $11.26M | -51.9% |
| Q4 FY2022 | Dec 31, 2022 | $18.52M | -37.6% |
| Q3 FY2022 | Sep 30, 2022 | $23.19M | -30.8% |
| Q2 FY2022 | Jun 30, 2022 | $19.42M | -45.8% |
| Q1 FY2022 | Mar 31, 2022 | $23.42M | +315.0% |
| Q4 FY2021 | Dec 31, 2021 | $29.69M | +238.9% |
| Q3 FY2021 | Sep 30, 2021 | $33.49M | +91419.7% |
| Q2 FY2021 | Jun 30, 2021 | $35.80M | +230294.1% |
| Q1 FY2021 | Mar 31, 2021 | $5.64M | +2750.9% |
| Q4 FY2020 | Dec 31, 2020 | $8.76M | +4538999.5% |
| Q3 FY2020 | Nov 30, 2020 | $36.60K | -72.8% |
| Q2 FY2020 | Aug 31, 2020 | $15.54K | -92.6% |
| Q1 FY2020 | May 31, 2020 | $197.98K | -27.7% |
| Q4 FY2019 | Dec 31, 2019 | $193 | -100.0% |
| Q3 FY2019 | Nov 30, 2019 | $134.31K | -36.4% |
| Q2 FY2019 | Aug 31, 2019 | $211.24K | – |
| Q1 FY2019 | May 31, 2019 | $273.69K | – |
| Q3 FY2018 | Nov 30, 2018 | $400.96K | – |
| Q2 FY2018 | Aug 31, 2018 | $211.24K | – |
| Q1 FY2018 | Mar 19, 2018 | $0 | – |
See a number that looks wrong?